People with bipolar disorder who take the blockbuster diabetes and weight-loss drug semaglutide experience a significant drop in psychiatric hospitalizations, according to a nationwide study published in June 2026 in Acta Psychiatrica Scandinavica. The research reveals that using the active ingredient found in Ozempic and Wegovy is associated with a 21 percent reduction in the risk of inpatient psychiatric care.
Swedish Health Data Reveals 21 Percent Drop in Hospitalizations
Researchers led by Professor Mark Taylor of Griffith University’s School of Medicine and Dentistry examined Swedish nationwide health records spanning from 2009 to 2024. The analysis tracked nearly 15,000 individuals diagnosed with bipolar disorder who received a prescription for a glucagon-like peptide-1 receptor agonist (GLP-1RA) during the 15-year study window.
According to Professor Taylor, patients with bipolar disorder exhibited significantly lower rates of psychiatric hospitalization during periods when they took semaglutide compared to times when they were not using the medication. Bipolar disorder affects roughly one in 200 people globally—amounting to an estimated 37 million individuals worldwide—and frequently involves severe episodes of depression and elevated or irritable moods that require inpatient treatment.
Mechanisms Beyond Metabolism Pointing to Brain Inflammation
While GLP-1 medications are primarily prescribed to regulate blood sugar, aid digestion, and suppress appetite, scientists are increasingly investigating how these signaling systems interact with the brain. Diabetes and obesity frequently co-occur with bipolar disorder, a clinical overlap driven by shared biological pathways involving inflammation, cellular stress, and metabolism.
The research team proposes that semaglutide may reduce inflammation and cellular stress inside the brain, which could help stabilize mood and prevent psychiatric relapses. However, the data showed that this mental health benefit was specific to semaglutide. Other medications in the same drug class, such as liraglutide and dulaglutide, did not demonstrate the same association with reduced psychiatric hospitalizations.
Next Steps for Clinical Research and Treatment
The findings highlight a promising new direction for psychiatric research, though experts emphasize that observational data cannot yet prove direct causation. Professor Taylor stated that the necessary next step is a randomized controlled trial. Such a trial would test whether semaglutide actively improves psychiatric outcomes and determine whether the drug could eventually play a formal role in comprehensive bipolar disorder management.
